Background. We evaluated outcomes of intraoperative radiotherapy delivered with focal high-dose-rate (HDR) brachytherapy [intraoperative radiotherapy (IORT)] in the management of locally recurrent (LR) and locally advanced (LA) primary T4 colorectal carcinoma (CRC). LR CRC or LA primary disease is a clinical challenge due to the difficulty in obtaining negative margins after radical surgery and the high risk of subsequent recurrence. Few data exist on long-term outcomes of patients treated with surgery and HDR-IORT for LR or LA primary CRC. Methods. Three hundred CRC patients underwent HDR-IORT to the pelvis with gross surgical resection during November 1992-December 2007. Median follow-up for surviving patients was 53 (range 5-216) months. Eightyeight patients (29 %) were treated for LA primary and 212 (71 %) LR disease. HDR-IORT was delivered using an iridium-192 remote afterloader and a Harrison-AndersonMick applicator. Median IORT dose was 1,500 (range 1,000-2,000) cGy. Results. Five-year overall survival probability was 49 %. Positive margin status was associated with inferior overall survival and disease-free survival. Competing-risks analysis for time to local failure and distant metastases identified a 5-year cumulative incidence of local failure and distant metastases of 33 and 47 %, respectively. Five-year cumulative incidence of local failure was 22 % for the LA group and 38 % in the LR group. Five-year probability of disease-free survival was 48 and 31 % for LA and LR patients, respectively, and 5-year probability of overall survival was 56 and 45 % for LA and LR patients, respectively.
cumulative incidence of local failure was 22 % for the LA group and 38 % in the LR group. Five-year probability of disease-free survival was 48 and 31 % for LA and LR patients, respectively, and 5-year probability of overall survival was 56 and 45 % for LA and LR patients, respectively. Conclusions. HDR-IORT combined with resection results in encouraging local control rates with acceptable toxicity for patients with locally aggressive CRC.
Patients with locally advanced (LA) primary T4 and locally recurrent (LR) colorectal cancer (CRC) are at high risk for local failure due to the potential for residual disease despite aggressive surgical resection. These tumors have a propensity to invade adjacent structures and adhere to the pelvic sidewall and sacrum, making complete surgical resection difficult. 1 Multiple studies have demonstrated that local control and survival is worse in patients with gross or microscopic residual disease after pelvic surgery. [1] [2] [3] [4] [5] [6] [7] The prescribed dose with external-beam radiotherapy (EBRT) is limited by the tolerance of surrounding normal tissues. Intraoperative radiation treatment (IORT) is a method used to escalate radiation dose to the tumor bed to address potential sites of residual disease while still respecting normal tissue tolerance. Delivering radiation at the time of surgery also allows intraoperative assessment by the surgeon and radiation oncologist to precisely delineate the tumor bed. Single-institution studies suggest the addition of IORT to multimodal therapy improves outcomes compared with historical controls in patients with LA or LR colorectal tumors. 1, 6 , [8] [9] [10] [11] [12] [13] Therefore, IORT has been integrated into the treatment paradigm for managing these difficult pelvic tumors.
We have previously reported the experience at Memorial Sloan-Kettering Cancer Center (MSKCC) with high-doserate (HDR) brachytherapy, and demonstrated encouraging results with a combined treatment strategy using EBRT, chemotherapy, surgical resection, and IORT. 12, 13 This study aims to report clinical outcomes for the populations of LA and LR CRC patients and to identify clinical characteristics associated with local control and survival with this multimodal approach to improve patient selection for this aggressive local therapy.
METHODS AND MATERIALS

Patient Characteristics
Between November 1992 and December 2007, 300 patients underwent gross surgical resection and HDR-IORT to the pelvis at MSKCC for either primary LA (n = 88) or LR (n = 212) CRC. After approval by the institutional review board, clinical information was obtained from the electronic medical record system and from an existing IORT database. The median follow-up for surviving patients was 53 (range 5-216) months. Two hundred sixty-four patients were followed for [1 year and 192 patients were followed for [2 years. Table 1 lists patient and treatment characteristics. Of the 212 LR cases of CRC, the majority of patients (n = 129) presented with disease in the rectum at initial diagnosis; the remaining patients had recurrent disease in the pelvis with an initial primary lesion in the colon (n = 46), rectosigmoid colon (n = 36), or cecum (n = 1). Thirty patients (10 %) had extrapelvic metastatic disease at diagnosis or before IORT. Patients with anal squamous cell carcinoma or who were administered IORT to treat extrapelvic recurrent disease were excluded from this analysis.
Treatment Characteristics
At the time of the operation with IORT, 234 patients (78 %) had undergone prior pelvic surgery. The surgical procedure at the time of IORT was an abdominoperineal resection in 101 patients, while 100 had low anterior resection, 60 had a pelvic exenteration, and 37 had wide local excision (Table 1) . Fourteen patients also underwent sacrectomy. Pathologic assessment was performed on all specimens after surgical resection by an MSKCC pathologist for delineation of nodal and margin status. Surgeon and operative assessments were reviewed in conjunction with pathology reports for identification of R0, R1, or R2 resection. R1 resection was further subdivided into close (B2 mm) margins or positive margins.
HDR-IORT was delivered using the Harrison-Anderson-Mick applicator. The MSKCC HDR-IORT technique NA pathologic assessment unavailable, IORT intraoperative radiotherapy a Some patients received more than one treatment at initial diagnosis, before IORT, and/or after IORT. Data are presented as n (%) for number and proportion of total patients/subgroup at each of the treatment periods has been previously published. 12, 13 The median IORT dose was 1,500 (range 1,000-2,000) cGy to a median target area of 30 (range 4-225) cm 2 . The dose was prescribed to 0.5 cm from the applicator surface (1 cm from the source). The median maximal tumor dimension was 5 (range 0.2-15) cm, and 44 patients (15 %) had multifocal satellite nodules. The median total treatment time for the IORT was 22 (range 5-83) min, and the median source insertion to removal time was 29 (range 7-91) min. The median total surgical procedure time was 480 (range 130-870) min, and the median hospital stay was 9 (range 4-45) days.
The paradigm for treatment of LA T4 patients involved delivery of preoperative chemoradiotherapy followed by surgical resection and IORT, and adjuvant chemotherapy. LR patients had predominantly received EBRT at initial diagnosis; those who had not received EBRT previously were treated with preoperative radiation at the time of local recurrence followed by surgical resection and IORT in addition to neoadjuvant and adjuvant chemotherapy (Table 1 ). Nearly all of the patients (96 %) had EBRT during their treatment course. Two hundred seventy-eight patients (92 %) underwent prior EBRT either at initial diagnosis or preoperatively with IORT; 11 (4 %) received EBRT after surgery and IORT. Median EBRT dose before IORT was 5,040 (range 3,060-7,020) cGy. Median postoperative EBRT dose was 4,500 (range 4,500-5,040) cGy. EBRT was generally delivered using 15 MV photons with a threeor four-field technique.
Two hundred eighty-one patients (94 %) received chemotherapy. All but six received 5-fluorouracil-based chemotherapy before surgery, and 132 (88 %) of 150 received it postoperatively. After 2003, oxaliplatin was routinely introduced into the chemotherapy regimens both pre-and post-operatively. Forty-seven patients received oxaliplatin either pre-or post-operatively, and 20 received oxaliplatin preoperatively.
Outcome Assessment
Follow-up clinical visits were conducted at intervals of 3-6 months by at least one physician from the surgical, radiation, or medical oncology departments. Computed tomographic scan of the abdomen and pelvis or magnetic resonance imaging of the pelvis was obtained at each 3-and 6-month interval. Follow-up was calculated from the date of HDR-IORT. Toxicity was assessed from clinical visit documentation and graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE, v.3.0). The highest grade given at any time was used in the analysis.
Statistical Analysis
For the end points of overall survival (OS) and diseasefree survival (DFS), a univariate analysis was first performed by the Cox proportional hazards model. A multivariate analysis (MVA) was performed by constructing a Cox model using a stepwise selection procedure. Variables with p \ 0.1 in the univariate analysis were used to build the multivariate model with a stepwise selection procedure. Variables were entered into the model if the score Chi-square statistic achieved a p value of B0.05 and were removed from the model if the Wald Chi-square statistic achieved a p value of C0.05.
A competing-risks analysis using R package cmprsk was performed for the end points of local control and time to distant metastasis. p values and 95 % confidence intervals were two-sided. p \ 0.05 was considered statistically significant. SAS 9.2 (SAS Institute, Cary, NC, USA) and R 2.9.2 were used for statistical analysis.
RESULTS
Local Control
A local pelvic recurrence developed in 94 (31 %) of all 300 patients; of these, 76 occurred in the 212 LR patients and 17 among the 88 LA patients. Of patients who experienced a local failure, 62 were not alive at last follow-up (69 %). One hundred (49 %) of 206 patients had locally controlled disease at time of death. The 5-year cumulative incidence of local failure was 22 % for the LA group and 38 % in the LR group. Positive margin status was associated with local failure on MVA for the LR group (hazard ratio, 2.28 [95 % confidence interval 1.39-3.37]) (Table 2) ; however, there were no factors significantly associated with local recurrence for the LA group (Table 3 ). The 5-year cumulative incidence of local failure in the LR group was 29 % for patients with negative margins, 35 % for close (B2 mm) margins, and 51 % for positive margins (p = 0.002 by Gray's method) ( Table 4) .
Distant Metastasis
Among 270 nonmetastatic patients with LA or LR disease, 122 developed distant metastases after IORT. The most common sites of distant failure were lung (53 %) and liver (22 %). The 5-year cumulative incidence of distant metastasis was 39 % for the LA group and 51 % for the LR group. Among the LR patients, a positive surgical margin and receipt of oxaliplatin was associated with a higher risk of developing distant metastasis on MVA. Only pathologically involved lymph node status was associated with an increased risk of distant metastases among the LA patients with a 5-year cumulative incidence of distant metastases of 63 and 32 % for node-positive and node-negative disease, respectively.
DFS and OS
The 5-year probability of DFS and the 5-year probability of OS for the overall population was 37 and was 49 %, respectively. The 5-year probability of DFS was 48 and 31 % for LA and LR patients, respectively (Fig 1) . A positive surgical margin (vs. negative margin) was associated with inferior DFS (p \ 0.0001) and OS (p \ 0.0001) on MVA for LR patients ( Table 2 ). The 5-year probability of DFS in patients with LR disease with a negative, close, or positive margin was 48, 35, and 7 %, respectively (Table 4 ; Fig. 2 ). The 5-year probability of DFS in patients with LA disease with a negative, close, or positive margin was 50, 44, and 45 %, respectively ( Table 5) .
The 5-year probability of OS was 56 and 45 % for LA and LR patients, respectively (Fig. 3) . The 5-year probability of OS in patients with LR disease with a negative, close, or positive margin was 57, 49, and 25 %, respectively (Table 4 ; Fig. 4 ). The 5-year probability of OS in patients with LA disease with a negative, close, or positive margin was 57, 45, and 60 %, respectively. Lymph node involvement and type of surgery were associated with OS for LA patients on MVA ( Table 3 ). The 5-year OS for LA patients with involved lymph nodes was 38 versus 62 % with node-negative disease (p = 0.02). In addition, LA patients undergoing low anterior resection had an improved OS compared with abdominoperineal resection (p = 0.03), likely representing the greater extent of disease in the abdominoperineal resection group.
Toxicity
Complications that could be related to the aggressive multimodal treatment regimen (surgery, IORT, EBRT, or concurrent chemoradiotherapy) were identified by any description in the medical record of signs or symptoms that could specifically be related to the surgical procedure during which IORT was performed. Toxicity data are reported in Table 6 . One patient in the series had a grade 5 toxicity associated with fistula formation. The incidence of toxicity was not significantly associated with radiation dose level.
DISCUSSION
LA and LR CRCs are challenging clinical entities and have a dismal prognosis when treated with surgery or radiation alone.
1,14-18 Local recurrence rates, even after combined EBRT and extensive pelvic surgery, are approximately 50 %. 19, 20 The morbidity of uncontrolled pelvic disease is frequently significant. As a result, a multimodal approach has evolved to aggressively treat these problematic tumors.
Isolating the magnitude of the benefit of IORT is extremely difficult, given the number of therapies these patients receive during their management course. Nonetheless, this management paradigm of radical resection with IORT resulted in excellent overall local control relative to historical data, particularly for patients with negative surgical margins. 4, [8] [9] [10] [11] [21] [22] [23] [24] In this study, the 5-year cumulative incidence of local failure was 22 % for patients with LA disease at presentation and 38 % for patients with LR disease at presentation. This is comparable to the results of the largest study of intraoperative electron radiotherapy published by Haddock et al. at the Mayo Clinic, in which 607 patients were evaluated with a median follow-up of 44 months for surviving patients and the 5-year local failure rate was 28 % for all patients. 25 However, a positive surgical margin remained a significant predictor for DFS and OS in patients with recurrent disease at presentation, which is consistent with multiple prior reports. [2] [3] [4] [5] [6] [7] More striking was the fact that the 5-year probability of DFS in patients with LR disease with a positive margin was 7 % and the 5-year probability of OS in patients LR disease with a positive margin was 25 %. The potential use of radiosensitizers could improve the therapeutic ratio in this setting, particularly in patients in whom a gross total resection may be difficult to achieve. Eighty-eight patients for LF and OS, and 82 for DFS; the latter value excludes 6 patients who had metastasis at initial diagnosis of rectal cancer or before surgery where they had IORT The findings in this study suggest that further improvement in local therapy for treatment of these LA tumors is warranted and that aggressive local treatment may affect survival.
Despite the relatively poor prognosis of patients presenting with recurrent or LA CRC, the overall 5-year OS was 49 and 53 % of patients were free of distant metastases at 5 years. However, outcomes were improved in patients with positive prognostic factors, such as negative surgical margins, in whom the 5-year OS was higher at 57 % for patients with recurrent disease at presentation. Patients with LR disease at presentation also fared worse than those with LA T4 disease at presentation with 5-year OS rates of 45 and 56 %, respectively. Therefore, there is incentive to approach these patients with definitive therapy. Effective local therapy may also improve quality of life for patients who may otherwise have significant morbidity as a result of local disease progression.
However, systemic failure still remains problematic for these patients, with a 5-year cumulative incidence of distant metastases of 47 % in this series; patients with LA disease had a 5-year cumulative incidence of distant metastases of 39 % compared to 51 % for patients with recurrent disease at presentation. This rate was similar to other studies despite aggressive use of chemotherapy in nearly all patients and the incorporation of oxaliplatin delivered either before or after surgery. 6, 23 Positive margin status was also significantly associated with systemic failure, suggesting that residual disease after local therapy may affect the development of distant metastases. To address the possible effect of systemic therapy, we examined the use of chemotherapy, era of treatment, and oxaliplatin use before chemotherapy, but these variables were not significant on univariate or multivariate analysis. Despite the important advances made to widen the options for systemic therapy and the encouraging results of oxaliplatin use, systemic failure remains problematic regardless of the effectiveness of local therapy.
Progressive tumors in the pelvis have the potential to cause significant morbidity; given that a considerable number of patients had locally controlled disease at the time of last follow-up, the rates of late toxicity in this report were quite reasonable. Evaluating toxicity resulting from IORT is extremely difficult, given the multiple therapies that these patients undergo, including EBRT, chemotherapy, and extensive surgical resection. The toxicities reported in this series are likely multifactorial, and in some patients, adverse effects from IORT may not be distinguished from toxicity resulting from surgery alone or from tumor progression. The rate of toxicities thought to be the result of IORT, including peripheral neuropathy and ureteral stenosis, were comparable in this study to other series in the literature. 2, 6, 22, [26] [27] [28] In an initial report from our institution, the overall rate of gastrointestinal, wound, and neurologic toxicities were similar to this updated series after the addition of over 200 patients and longer followup. 12 There was no association between IORT dose level and incidence of toxicity, which is consistent with the findings from prior reports from our institution. 12, 13, 29 Ideally, a randomized controlled trial would elucidate the impact of IORT on local control and survival of patients with LA and LR CRC. However, given the heterogeneity of this patient population and the limited availability of IORT, it is unlikely that large patient numbers will ever be accrued to complete such a study. There has been one phase 3 randomized trial of IORT performed in the setting of primary LA (T3-4 or node positive) disease, which showed no difference in local control rates with the addition of IORT at the time of surgical resection after preoperative chemoradiotherapy; however, the local failure rate for the control arm was only 7 %, so this study of 142 patients was underpowered to show a benefit in this low-risk population. 30 In addition, there was a large percentage of T3 patients included in this study, which are not typically the ideal candidates for an IORT boost. There was no difference in surgical complications between the arms. The authors concluded that the technique should be reserved for cases at a higher risk of local recurrence. Multiple studies have demonstrated excellent local control in a patient population with LA disease using a management strategy incorporating IORT. 6, [8] [9] [10] [11] [12] [13] 31 Moreover, the majority of patients in our study had recurrent disease, which is associated with even greater surgical challenges as a result of the disrupted fascial planes and postoperative fibrosis and adhesions. As shown in our study, these patients have a higher risk of local recurrence and may benefit more from the IORT. Therefore, in the absence of a large, well-powered, randomized study including patients with recurrent CRC, we continue to recommend an aggressive treatment approach using IORT as a definitive strategy in these potentially curable patients. We continue to evaluate novel techniques to deliver HDR-IORT more focally and have previously reported on a dose-painting HDR-IORT technique. 32 With the Harrison-AndersonMick applicator, dose can be sculpted inside of the target area, permitting dose escalation or de-escalation, allowing for planned non-homogenous dose distributions or dose painting. This technique allows for sites suspicious for residual microscopic disease to be treated to higher doses while minimizing dose to normal organs, which may improve outcomes for patients with positive margins who remain at highest risk of recurrence.
Aggressive local therapy combining EBRT, chemotherapy, surgery, and IORT in this challenging patient population results in excellent local control and acceptable toxicity rates. Given the potential for morbidity in the setting of local progression in the pelvis in patients with LA T4 lesions or recurrent colorectal tumors, these patients should be referred for evaluation for definitive multimodal therapy.
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